{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:18:27Z","timestamp":1792552707707,"version":"4.5.0"},"reference-count":66,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec id=\"ab-poi250051-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Human papillomavirus (HPV) vaccine clinical trials demonstrate high vaccine efficacy, but postlicensure population-level effectiveness data are needed to inform vaccination and cancer-prevention recommendations and policies. Little is known about effectiveness in adolescent girls and young adult women at high risk for HPV-related cancers or after 9-valent HPV vaccine (9vHPV) introduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi250051-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine effectiveness and herd protection over the first 17 years after HPV vaccine introduction in adolescent girls and young women at increased risk for HPV infection and related cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi250051-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cross-sectional study analyzed data from 6 surveillance studies from 2006 to 2023. A consecutive sample of sexually experienced adolescent girls and young women aged 13 to 26 years was recruited from clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi250051-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Participants were stratified by HPV vaccination status; those who received at least 1 vaccine dose were defined as vaccinated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi250051-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Effectiveness and herd protection were assessed by comparing proportions of vaccinated and unvaccinated participants positive for at least 1 type in the 2-valent vaccine (2vHPV), 4-valent vaccine (4vHPV), and 9vHPV in each of 6 studies. The prevalence of vaccine-type HPV was compared in vaccinated participants from surveillance studies 2 through 6 vs participants recruited in surveillance study 1, all of whom were unvaccinated. Inverse probability of treatment weighting with propensity score was used to balance between-wave differences in participant characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi250051-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2335 participants (mean [SD] age, 18.9 [2.7] years; 1526 African American [65.4%], 13 Asian [0.6%], 6 Native American [0.3%], 582 White [24.9%], and 151 multiracial [6.5%]; 173 Hispanic [7.4%]), 1195 participants (51.2%) reported a sexually transmitted infection history and 1843 participants (78.9%) reported 2 or more male sex partners. Vaccination rates increased from 0 of 371 participants to 330 of 402 participants (82.1%) from 2006 to 2023. Among vaccinated participants, positivity decreased from 93 of 371 participants (27.7%) to 1 of 330 participants (0.4%) for 2vHPV (relative difference, 98.4%), 118 participants (35.4%) to 3 participants (2.1%) for 4vHPV (relative difference, 94.2%), and 163 participants (48.6%) to 21 participants (11.8%) for 9vHPV (relative difference, 75.7%). Among unvaccinated participants, positivity decreased from 93 of 371 participants (25.8%) to 3 of 72 participants (7.3%) for 2vHPV (relative difference, 71.6%), 118 participants (25.3%) to 4 participants (6.1%) for 4vHPV (relative difference, 75.8%), and 163 participants (42.7%) to 13 participants (31.1%) for 9vHPV (relative difference, 27.2%). For positivity rates, counts are raw numbers and percentages are propensity score adjusted. Adjusted logistic regression demonstrated significant reductions in the odds of at least 1 HPV type in the 2vHPV and 4vHPV among all (adjusted odds ratio [aOR], 0.03; 95% CI, 0.01 to 0.07 and aOR, 0.06; 95% CI, 0.03 to 0.10, respectively), vaccinated (aOR, 0.01; 95% CI, &amp;amp;lt;0.01 to 0.05 and aOR, 0.04; 95% CI, 0.02 to 0.08, respectively), and unvaccinated (aOR, 0.23; 95% CI, 0.08 to 0.63 and aOR, 0.19; 95% CI, 0.07 to 0.52, respectively) participants and in the 9vHPV among all (aOR, 0.22; 95% CI 0.16 to 0.31) and vaccinated (aOR, 0.14; 95% CI 0.09 to 0.21) participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-poi250051-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this study, population-level effectiveness and herd protection were robust 17 years after HPV vaccine introduction, even in sexually experienced adolescent girls and young women at relatively high risk for HPV who may not have received the full vaccination series.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamapediatrics.2025.3568","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:30:57Z","timestamp":1759159857000},"page":"1326","source":"Crossref","is-referenced-by-count":14,"title":["Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction"],"prefix":"10.1001","volume":"179","author":[{"given":"Aislinn","family":"DeSieghardt","sequence":"first","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Ding","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ermel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[{"name":"Gerald Bonfman Department of Oncology, McGill University, Montreal, Quebec, Canada"},{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Dagnall","sequence":"additional","affiliation":[{"name":"Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland"},{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darron R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sem","family":"Yao","sequence":"additional","affiliation":[{"name":"Western Reserve Hospital, Cuyahoga Falls, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Kahn","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"},{"name":"Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"poi250051r1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/v16050680","article-title":"Human papillomavirus and associated cancers: a review.","volume":"16","author":"Jensen","year":"2024","journal-title":"Viruses"},{"issue":"2","key":"poi250051r2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.idc.2023.02.008","article-title":"Sexually transmitted human papillomavirus: update in epidemiology, prevention, and management.","volume":"37","author":"Plotzker","year":"2023","journal-title":"Infect Dis Clin North Am"},{"issue":"10451","key":"poi250051r3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"poi250051r4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type.","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"issue":"2","key":"poi250051r5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jnma.2020.03.002","article-title":"A review of cervical cancer: incidence and disparities.","volume":"112","author":"Buskwofie","year":"2020","journal-title":"J Natl Med Assoc"},{"issue":"6","key":"poi250051r6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"poi250051r7","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"49","key":"poi250051r8","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination\u2014updated recommendations of the Advisory Committee on Immunization Practices.","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"32","key":"poi250051r9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices.","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9518","key":"poi250051r11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"52","key":"poi250051r12","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"issue":"9574","key":"poi250051r13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"issue":"9686","key":"poi250051r14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"poi250051r15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"poi250051r16","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities.","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"poi250051r17","doi-asserted-by":"publisher","first-page":"918","DOI":"10.7326\/M21-3798","article-title":"Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018.","volume":"175","author":"Rosenblum","year":"2022","journal-title":"Ann Intern Med"},{"key":"poi250051r18","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1086\/425271","article-title":"Role of herd immunity in determining the effect of vaccines against sexually transmitted disease.","volume":"191","author":"Garnett","year":"2005","journal-title":"J Infect Dis"},{"issue":"6","key":"poi250051r19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S1473-3099(10)70318-2","article-title":"New approaches to the assessment of vaccine herd protection in clinical trials.","volume":"11","author":"Clemens","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"poi250051r20","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1542\/peds.2011-3587","article-title":"Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction.","volume":"130","author":"Kahn","year":"2012","journal-title":"Pediatrics"},{"issue":"10","key":"poi250051r21","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/cid\/ciw533","article-title":"Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community.","volume":"63","author":"Kahn","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"poi250051r22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/OLQ.0000000000000731","article-title":"Non-vaccine-type human papillomavirus prevalence after vaccine introduction: no evidence for type replacement but evidence for cross-protection.","volume":"45","author":"Saccucci","year":"2018","journal-title":"Sex Transm Dis"},{"issue":"2","key":"poi250051r23","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-1902","article-title":"Human papillomavirus vaccine effectiveness and herd protection in young women.","volume":"143","author":"Spinner","year":"2019","journal-title":"Pediatrics"},{"issue":"7-8","key":"poi250051r24","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1080\/21645515.2018.1564438","article-title":"Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.","volume":"15","author":"Covert","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"poi250051r25","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/ijc.31989","article-title":"Assessment of herd effects among women and heterosexual men after girls-only HPV16\/18 vaccination in the Netherlands: a repeated cross-sectional study.","volume":"144","author":"Woestenberg","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"poi250051r26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1158\/1940-6207.CAPR-21-0063","article-title":"Reduction in vaccine HPV type infections in a young women group (18-25 years) five years after HPV vaccine introduction in Colombia.","volume":"15","author":"Combita","year":"2022","journal-title":"Cancer Prev Res (Phila)"},{"key":"poi250051r27","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1204101","article-title":"Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017\/2018: results from a nationwide study.","volume":"11","author":"Loenenbach","year":"2023","journal-title":"Front Public Health"},{"issue":"45","key":"poi250051r28","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.1016\/j.vaccine.2023.10.002","article-title":"The impact of over ten years of HPV vaccination in England: surveillance of type-specific HPV in young sexually active females.","volume":"41","author":"Checchi","year":"2023","journal-title":"Vaccine"},{"issue":"5","key":"poi250051r29","first-page":"513","article-title":"Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.","volume":"163","author":"Sellors","year":"2000","journal-title":"CMAJ"},{"issue":"5 Pt 1","key":"poi250051r30","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/01.AOG.0000124569.61462.8d","article-title":"Comparison of adolescent and young adult self-collected and clinician-collected samples for human papillomavirus.","volume":"103","author":"Kahn","year":"2004","journal-title":"Obstet Gynecol"},{"issue":"9","key":"poi250051r31","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/v15091889","article-title":"Accuracy of human papillomavirus (HPV) testing on urine and vaginal self-samples compared to clinician-collected cervical sample in women referred to colposcopy.","volume":"15","author":"Martinelli","year":"2023","journal-title":"Viruses"},{"issue":"10","key":"poi250051r32","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1128\/JCM.36.10.3020-3027.1998","article-title":"Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.","volume":"36","author":"Gravitt","year":"1998","journal-title":"J Clin Microbiol"},{"issue":"1","key":"poi250051r33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1128\/JCM.38.1.357-361.2000","article-title":"Improved amplification of genital human papillomaviruses.","volume":"38","author":"Gravitt","year":"2000","journal-title":"J Clin Microbiol"},{"issue":"3","key":"poi250051r34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/pan\/mpl013","article-title":"Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference.","volume":"15","author":"Ho","year":"2007","journal-title":"Polit Anal"},{"issue":"8","key":"poi250051r35","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research.","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"19","key":"poi250051r36","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models.","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"3","key":"poi250051r37","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/biomet\/87.3.706","article-title":"The role of the propensity score in estimating dose-response functions.","volume":"87","author":"Imbens","year":"2000","journal-title":"Biometrika"},{"issue":"12","key":"poi250051r38","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models.","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"3","key":"poi250051r39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"47","key":"poi250051r40","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1016\/j.vaccine.2012.08.045","article-title":"Distinguishing vaccine efficacy and effectiveness.","volume":"30","author":"Shim","year":"2012","journal-title":"Vaccine"},{"issue":"48","key":"poi250051r41","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1016\/j.vaccine.2013.07.006","article-title":"Vaccine effects and impact of vaccination programmes in post-licensure studies.","volume":"31","author":"Hanquet","year":"2013","journal-title":"Vaccine"},{"issue":"10224","key":"poi250051r42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"poi250051r43","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/cid\/ciab434","article-title":"High prevalence of anal high-grade squamous intraepithelial lesions, and prevention through human papillomavirus vaccination, in young men who have sex with men living with human immunodeficiency virus.","volume":"73","author":"Palefsky","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"poi250051r44","first-page":"14","article-title":"The impact of HPV vaccination on the prevention of oropharyngeal cancer: a scoping review.","volume":"39","author":"Kaczmarczyk","year":"2022","journal-title":"Community Dent Health"},{"issue":"4","key":"poi250051r45","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/1557988316645155","article-title":"Factors associated with HPV vaccine initiation, vaccine completion, and accuracy of self-reported vaccination status among 13- to 26-year-old men.","volume":"12","author":"Thomas","year":"2018","journal-title":"Am J Mens Health"},{"issue":"29","key":"poi250051r46","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1016\/j.vaccine.2019.04.099","article-title":"Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: evidence of direct and herd effects of vaccination.","volume":"37","author":"Markowitz","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"poi250051r47","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1080\/14760584.2022.2129615","article-title":"Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review.","volume":"21","author":"Wang","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"poi250051r48","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2308378","article-title":"High impact of quadrivalent human papillomavirus vaccine across racial\/ethnic groups: National Health and Nutrition Examination Survey, 2003-2006 and 2015-2018.","volume":"20","author":"Stefanos","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"poi250051r49","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"10197","key":"poi250051r50","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"poi250051r51","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/infdis\/jiaa099","article-title":"Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied.","volume":"222","author":"V\u00e4nsk\u00e4","year":"2020","journal-title":"J Infect Dis"},{"issue":"37","key":"poi250051r52","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1016\/j.vaccine.2022.06.065","article-title":"Human papillomavirus vaccine effectiveness by number of doses: updated systematic review of data from national immunization programs.","volume":"40","author":"Markowitz","year":"2022","journal-title":"Vaccine"},{"key":"poi250051r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2024.100486","article-title":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: an updated systematic review of evidence from clinical trials.","volume":"19","author":"Whitworth","year":"2024","journal-title":"Vaccine X"},{"issue":"7","key":"poi250051r54","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/infdis\/jix057","article-title":"Prevalence of genital human papillomavirus in males, United States, 2013-2014.","volume":"215","author":"Gargano","year":"2017","journal-title":"J Infect Dis"},{"issue":"12","key":"poi250051r55","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"poi250051r56","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciaa1770","article-title":"Population impact of girls-only human papillomavirus 16\/18 vaccination in the Netherlands: cross-protective and second-order herd effects.","volume":"72","author":"Hoes","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"12","key":"poi250051r57","doi-asserted-by":"publisher","first-page":"415","DOI":"10.15585\/mmwr.mm7012a2","article-title":"Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine\u2014United States, 2003-2018.","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"poi250051r58","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.","volume":"1","author":"Brisson","year":"2016","journal-title":"Lancet Public Health"},{"issue":"10","key":"poi250051r59","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70022","article-title":"Continuous global improvement of human papillomavirus (HPV) genotyping services: the 2022 and 2023 HPV LabNet international proficiency studies.","volume":"96","author":"Arroyo M\u00fchr","year":"2024","journal-title":"J Med Virol"},{"issue":"10","key":"poi250051r60","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/infdis\/jiz324","article-title":"Evaluation of TypeSeq, a novel high-throughput, low-cost, next-generation sequencing-based assay for detection of 51 human papillomavirus genotypes.","volume":"220","author":"Wagner","year":"2019","journal-title":"J Infect Dis"},{"issue":"5","key":"poi250051r61","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01794-18","article-title":"Development of the TypeSeq assay for detection of 51 human papillomavirus genotypes by next-generation sequencing.","volume":"57","author":"Wagner","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"2","key":"poi250051r62","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ijc.34698","article-title":"A rapid HPV typing assay to support global cervical cancer screening and risk-based management: a cross-sectional study.","volume":"154","author":"Inturrisi","year":"2024","journal-title":"Int J Cancer"},{"issue":"10316","key":"poi250051r63","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"issue":"41","key":"poi250051r64","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","volume":"23","author":"Patel","year":"2018","journal-title":"Euro Surveill"},{"issue":"1","key":"poi250051r65","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/ijc.33513","article-title":"Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: an ecological analysis on the effects of the school-based human papillomavirus vaccination program.","volume":"149","author":"Donken","year":"2021","journal-title":"Int J Cancer"},{"key":"poi250051r10","unstructured":"World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. December 16, 2022. Accessed August 21, 2025. https:\/\/www.who.int\/publications\/i\/item\/who-wer9750-645-672"},{"key":"poi250051r66","unstructured":"World Health Organization. Immunization, vaccines and biologicals: HPV dashboard. Accessed August 21, 2025. https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/human-papillomavirus-vaccines-(HPV)\/hpv-clearing-house\/hpv-dashboard"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2839024\/jamapediatrics_desieghardt_2025_oi_250051_1763487239.88.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:00:49Z","timestamp":1764604849000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2839024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2025.3568","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}